A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-523 in Treatment of Primary Immune Thrombocytopenia (ITP) in Adults (ESLIM-01 Study)
Latest Information Update: 12 May 2026
At a glance
- Drugs Sovleplenib (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Acronyms ESLIM-01
- Sponsors HUTCHMED
Most Recent Events
- 04 May 2026 Status changed from active, no longer recruiting to completed.
- 19 Mar 2025 According to a HUTCHMED media release, company expects Complete ESLIM-01 NMPA NDA review around end 2025.
- 17 Mar 2025 Planned End Date changed from 30 Jun 2025 to 30 May 2025.